- Conditions
- Alzheimer's Disease
- Interventions
- Semorinemab, Placebo, [18F]GTP1
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 457 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Glendale, California • Irvine, California + 39 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 280
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Virus Diseases
- Interventions
- Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Lowest dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Saline Placebo, RabAvert
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 4
- States / cities
- South Miami, Florida • Lenexa, Kansas • Baltimore, Maryland + 1 more
- Conditions
- Neurofibromatoses
- Interventions
- Part 1 Levulan injection, Part 1 Levulan surface application, Part 1 Levulan surface application twice, Part 1 Levulan surface application twice with microneedling, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3
- Drug
- Lead sponsor
- Harry T Whelan, MD
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- End Stage Kidney Disease, Depressive Symptoms
- Interventions
- Joviality(TM), Inert Virtual Reality
- Behavioral · Other
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Chicago, Illinois
- Conditions
- Hepatitis C, HIV Infections
- Interventions
- telaprevir or matching placebo, peginterferon alfa-2a, ribavirin (fixed dose), ribavirin (weight-based dose)
- Drug · Biological
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 11
- States / cities
- Beverly Hills, California • San Diego, California • San Francisco, California + 8 more
- Conditions
- Urinary Tract Infections
- Interventions
- Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine low dose formulation 2, Candidate UTI vaccine medium dose formulation 1, Candidate UTI vaccine medium dose formulation 2, Candidate UTI vaccine high dose formulation 1, Candidate UTI vaccine high dose formulation 2, Candidate UTI vaccine HTD formulation 2, Placebo
- Combination Product
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 448 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 6
- States / cities
- Lenexa, Kansas • Secaucus, New Jersey • Rochester, New York + 3 more
- Conditions
- Alzheimer's Disease
- Interventions
- TC-5619, Placebo
- Drug
- Lead sponsor
- Targacept Inc.
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 10
- States / cities
- Long Beach, California • San Francisco, California • Hallandale, Florida + 7 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Placebo, SRP-4053
- Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 6 Years to 15 Years · Male only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hemorrhagic Fever, Ebola
- Interventions
- Ad26.ZEBOV, MVA-BN-Filo, Placebo
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 578 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Asthma
- Interventions
- Reslizumab, Fludeoxyglucose F 18 (FDG), Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria, Muckle-Wells Syndrome (MWS), Genetic Diseases, Inborn
- Interventions
- rilonacept 160 mg, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 7 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 24
- States / cities
- Little Rock, Arkansas • Palm Desert, California • Upland, California + 21 more
- Conditions
- Orthopaedic Fractures
- Interventions
- NSAID, Gabapentinoids, placebo
- Drug
- Lead sponsor
- Major Extremity Trauma Research Consortium
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 17
- States / cities
- Miami, Florida • West Palm Beach, Florida • Indianapolis, Indiana + 13 more
- Conditions
- APOL1-Mediated Kidney Disease
- Interventions
- AZD2373-Arm 1, AZD2373-Arm 2, Placebo, APOL1 Genotyping Clinical Trial Assay
- Combination Product · Device
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 86
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Irondale, Alabama + 73 more
- Conditions
- Depressive Disorder, Major
- Interventions
- JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more
- Conditions
- Parkinson Disease
- Interventions
- HL-400, Placebo
- Drug
- Lead sponsor
- Highlightll Pharmaceutical (USA) LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Classic Galactosemia
- Interventions
- AT-007, Placebo
- Drug · Other
- Lead sponsor
- Applied Therapeutics, Inc.
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Ann Arbor, Michigan
- Conditions
- Ulcerative Colitis
- Interventions
- UTTR1147A, UTTR1147A Placebo, Vedolizumab, Vedolizumab Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Greenville, North Carolina • Salt Lake City, Utah
- Conditions
- HIV Infections
- Interventions
- Cabotegravir sodium (Oral Lead In), Cabotegravir 400 mg/mL, Cabotegravir 200 mg/mL, Topical Non-steroidal anti-inflammatory drug (NSAID), Topical steroid, Topical NSAID placebo, Recombinant human hyaluronidase PH20 (rHuPH20), Topical steroid placebo
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 4
- States / cities
- Orlando, Florida • Las Vegas, Nevada • Berlin, New Jersey + 1 more
- Conditions
- Anemia
- Interventions
- Sotatercept, Placebo
- Biological
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 24
- States / cities
- Azusa, California • Glendale, California • La Mesa, California + 16 more
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- Bocidelpar, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 8 Years to 16 Years · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 5
- States / cities
- Sacramento, California • Kansas City, Kansas • Baltimore, Maryland + 2 more
- Conditions
- Methamphetamine-dependence
- Interventions
- Ibudilast, Placebo Oral Tablet
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- BKR-013 or Placebo
- Other
- Lead sponsor
- BioKier Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease
- Interventions
- PF-06865571, PF-05221304, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 11
- States / cities
- Lincoln, California • Montclair, California • Boca Raton, Florida + 7 more
- Conditions
- West Nile Fever
- Interventions
- ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose, 0.9% Saline solution, 0.9 % NaCl solution
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2009
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Idaho Falls, Idaho • Lenexa, Kansas + 2 more